Please login to the form below
AR101
This page shows the latest AR101 news and features for those working in and with pharma, biotech and healthcare.
EU authorises Aimmune’s peanut allergy treatment Palforzia
The oral immunotherapy – previously known as AR101 – takes the form of defatted peanut flour that is sprinkled over food, given in tiny but gradually increasing amounts over a six-month period,
Latest news
-
Nestlé is set to acquire Aimmune in deal worth $2.6bn
Palforzia, previously known as AR101, was approved by the US Food and Drug Administration (FDA) in January for use in children aged four to 17 with a confirmed diagnosis of peanut
-
Aimmune’s Palforzia is first peanut allergy drug cleared in US
The oral immunotherapy – previously known as AR101 – takes the form of defatted peanut flour that is sprinkled over food, given in tiny but gradually increasing amounts over a six-month period,
-
Aimmune gets FDA panel backing for peanut allergy therapy
The panel voted seven to two that AR101 – now given the trade name Palforzia – can reduce allergic reactions from accidental exposure to peanuts and warrants approval. ... The FDA is due to make a decision on AR101 in January, and usually, but not
-
DBV refiles peanut allergy immunotherapy in the US
Both candidates have breakthrough status, meaning that they will be granted speedy reviews and, unless there is another mishap, Aimmune should now get its AR101 therapy to the US market first ... Aimmune is expecting an approval decision on AR101 by
-
Aimmune preps EU filing for peanut allergy immunotherapy
CEO Jayson Dallas. No cases of serious effects such as anaphylaxis or of eosinophilic esophagitis (EoE) were observed during the study, further reinforcing AR101’s profile. ... He adds: “If approved, AR101 could significantly reduce their risk of
More from news
Approximately 1 fully matching, plus 7 partially matching documents found.
Latest Intelligence
-
Drug launches to watch in 2019
conditions. 2. AR101 – the first peanut allergy treatment. Potentially deadly allergies to food and other everyday substances are on the rise around the world – and there are currently very few therapies ... Analysts say the market could eventually
More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.
Latest from PMHub
-
Food Allergy – Is avoidance the only option?
AR101 Oral Immunotherapy for Peanut Allergy. N Engl J Med. 2018; 379(21):1991-2001. ... Efficacy and safety of oral immunotherapy with AR101 in European children with a peanut allergy (ARTEMIS): a multicentre, double-blind, randomised, placebo-controlled
More from PMHub
Approximately 0 fully matching, plus 1 partially matching documents found.
Subscribe to our email news alerts
-
Pharmacovigilance Project Lead
- Highly competitive salary
- Strategy Director - Healthcare Advertising
- £90,000 - £120,000 yearly
-
Omnichannel Account Director
- £55,000 - £65,000 yearly
-
Pharmacovigilance Manager
- Highly competitive salary
- Associate Director - Global Healthcare Consulting
- £100,000 - £115,000 yearly
- Early Access Program - Regulatory Affairs (EAP-RA)
- Highly competitive salary
-
Technical Sales Representative
- Highly competitive salary
-
Senior Medical Writer
- Highly competitive salary
- AbbVie’s Parkinson’s disease therapy application rejected by FDA
- FDA proposes improvements for oncology clinical trials supporting accelerated approval
- Italy accelerates the path towards digital therapeutics implementation
- Novo Nordisk and Dewpoint partner on insulin resistance drug candidates
- Takeda presents positive phase 2b results for TAK-279 in plaque psoriasis
- AstraZeneca/MSD’s Lynparza combination approved in UK for prostate cancer
- The speed of science and the pace of comms
- MSD’s Keytruda to be made available in England for advanced cervical cancer patients
- Boehringer Ingelheim and Covant to collaborate on cancer immunotherapies
- Eli Lilly increases investment to almost $1bn for new Irish manufacturing facility
- Regeneron and Sonoma Biotherapeutics partner on autoimmune disease therapies
- Improving cardiovascular disease care and awareness
- Team ITG appoints Gerhard Arnhofer as head of customer strategy for life sciences division
- Eli Lilly increases investment to almost $1bn for new Irish manufacturing facility
- Locus Biosciences announces first patient treated in urinary tract infection trial
- Novo Nordisk and Dewpoint partner on insulin resistance drug candidates
- Roche and Eli Lilly to collaborate on Alzheimer’s disease blood test
- UCB's bimekizumab shows continued improvement in hidradenitis suppurativa patients
PMHub
Wave Healthcare Communications
Wave combine scientific, medical and brand expertise to deliver clinically focused programmes that are trusted by HCPs, drive better patient...
Latest intelligence
- The speed of science and the pace of comms
- Pharma red tape slows comms but there is a solution, Paul Hutchings, founder of fox&cat, writes....
- Improving cardiovascular disease care and awareness
- Scott Curley talks to PME about the risks of CVD and the importance of getting the right treatment at the right time...
- Virtual Patient Engagement Program: A Customer Story
- Our client wanted to better understand the needs, preferences, and treatment gaps among adult patients with a rare genetic disease......
